文献速递白血病

联合社会人口学与临床协变量预测慢性期慢性髓性白血病患者的治疗反应与结局

[Combination of socio-demographic and clinical co-variates for predicting treatment responses and outcomes in patients with chronic myeloid leukemia in the chronic phase].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2022-01-01

回顾性分析2006年1月至2020年12月北京大学人民医院1414例初诊接受一线TKI治疗的成人CML-CP连续病例,采用Cox模型探索治疗反应与结局的独立影响因素,并联合社会人口学与临床因素建立预测模型,亚组间治疗反应及结局差异均有统计学意义(P<0.001)。

要点

  • 受教育水平低和ELTS评分中/高危与较低CCyR、MMR、MR(4)、MR(4.5)获得率及不良结局相关。
  • 男性、农村户籍、WBC≥120×10(9)/L、HGB<115 g/L和一线伊马替尼与较低细胞遗传学/分子学反应获得率相关。
  • 联合社会人口学与临床因素建立的模型可预测治疗反应及结局,亚组间差异P<0.001。

核心结论

  • 除临床因素外,社会人口学因素与CML-CP患者TKI治疗反应及结局密切相关。
  • 联合社会人口学因素与临床特征可较好预测患者的治疗反应及结局。

研究设计与样本

  • 回顾性分析2006年1月至2020年12月北京大学人民医院确诊的≥18岁初诊接受TKI一线治疗、具有完整社会人口学及临床资料的CML-CP连续病例。
  • 共纳入1414例,一线伊马替尼1176例、尼洛替尼170例、达沙替尼68例;中位年龄40(18~83)岁,男性873例(61.7%)。
  • 应用Cox回归模型探索治疗反应和结局的独立影响因素。

主要发现

  • 受教育水平低(P<0.001~0.070)和ELTS评分中/高危(P<0.001~0.009)是较低CCyR、MMR、MR(4)、MR(4.5)获得率及不良FFS、PFS、OS、CML-OS的共同影响因素。
  • 男性、农村户籍、初诊WBC≥120×10(9)/L、HGB<115 g/L和一线伊马替尼与较低细胞遗传学和(或)分子学反应获得率显著相关。
  • 单身、离异或寡居、农村户籍、初诊WBC≥120×10(9)/L、HGB<115 g/L和伴有合并症与较低FFS、PFS、OS和(或)CML-OS率显著相关。
  • 联合社会人口学及临床因素建立预测模型并将患者分为各风险亚组,亚组间治疗反应及结局差异均具有统计学意义(P<0.001)。

关键数值与推荐

  • 治疗反应指标包括CCyR、MMR、MR(4)、MR(4.5),结局指标包括FFS、PFS、OS、CML-OS。
  • 受教育水平低对应P<0.001~0.070,ELTS评分中/高危对应P<0.001~0.009。
  • 亚组间治疗反应及结局差异P<0.001。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the impacts of socio-demographic and clinical co-variates on treatment responses and outcomes in patients with chronic myeloid leukemia in the chronic phase (CML-CP) receiving tyrosine kinase inhibitor (TKI) and identified the predictive models for them. Methods: Data of newly diagnosed adult patients with CML-CP receiving first-line TKI and having complete socio-demographic data and clinical information were reviewed. Cox model was used to identify the independent variables associated with complete cytogenetic response (CCyR) , major molecular response (MMR) , molecular response 4 (MR(4)) and molecular response 4.5 (MR(4.5)) , as well as failure-free survival (FFS) , progression-free survival (PFS) , overall survival (OS) and CML-related OS. Results: A total of 1414 CML-CP patients treated with first-line imatinib (n=1176) , nilotinib (n=170) or dasatinib (n=68) were reviewed. Median age was 40 (18-83) years and 873 patients (61.7% ) were males. Result of the multivariate analysis showed that lower educational level (P<0.001-0.070) and EUTOS long-term survival intermediate or high-risk (P<0.001-0.009) were significantly associated with lower cumulative incidences of CCyR, MMR, MR(4) and MR(4.5), as well as the inferior FFS, PFS, OS and CML-related OS. In addition, those who were males, from rural households, had white blood cells (WBC) ≥120×10(9)/L, hemoglobin (HGB) <115 g/L and treated with first-line imatinib had significantly lower cumulative incidences of cytogenetic and/or molecular responses. Being single, divorced or widowed, having, rural household registration, WBC≥120×10(9)/L, HGB<15 g/L, and comorbidity (ies) was significantly associated with inferior FFS, PFS, OS, and/or CML-related OS. Thereafter, the patients were classified into several subgroups using the socio-demographic characteristics and clinical variables by cytogenetic and molecular responses, treatment failure and disease progression, as well as overall survival and CML-related OS, respectively. There were significant differences in treatment responses and outcomes among the subgroups (P<0.001) . Conclusion: Except for clinical co-variates, socio-demographic co-variates significantly correlated with TKI treatment responses and outcomes in CML-CP patients. Models established by the combination of independent socio-demographic and clinical co-variates could effectively predict the responses and outcome. 目的: 探讨影响初发慢性髓性白血病慢性期(CML-CP)治疗反应及结局的社会人口学因素及临床因素,并联合社会人口学因素及临床因素分别建立针对治疗反应及结局新的预测模型。 方法: 回顾性分析2006年1月至2020年12月在北京大学人民医院确诊的≥18岁初诊接受酪氨酸激酶抑制剂(TKI)一线治疗、具有完整社会人口学及临床资料的CML-CP连续病例。应用Cox回归模型探索治疗反应和结局的独立影响因素,治疗反应包括完全细胞遗传学反应(CCyR)、主要分子学反应(MMR)、分子学反应4(MR(4))、分子学反应4.5(MR(4.5)),结局包括无失败生存(FFS)、无进展生存(PFS)、总生存(OS)、CML相关生存(CML-OS)。 结果: 研究共纳入1414例以伊马替尼(1176例)、尼洛替尼(170例)或达沙替尼(68例)为一线治疗的成人CML-CP患者,中位年龄40(18~83)岁,男性873例(61.7%)。多因素分析显示,受教育水平低(P值<0.001 ~ 0.070)和ELTS评分中/高危(P值<0.001~0.009)是较低的细胞遗传学、分子学反应获得率以及各种不良治疗结局的共同影响因素。此外,男性、农村户籍以及初诊时WBC≥120×10(9)/L、HGB<115 g/L和一线伊马替尼治疗与较低的细胞遗传学反应和(或)分子学反应获得率均显著相关;单身、离异或丧偶、农村户籍以及初诊时WBC≥120×10(9)/L、HGB<115 g/L和伴有合并症与较低的FFS、PFS、OS和(或)CML-OS率显著相关。联合社会人口学因素及临床因素分别建立针对治疗反应、治疗失败及疾病进展以及生存的预测模型,根据上述预测模型将整体患者分为各风险亚组,亚组间治疗反应及结局差异均具有统计学意义(P值均<0.001)。 结论: 除临床因素外,社会人口学因素与CML-CP患者治疗反应及结局密切相关。联合社会人口学因素与临床特征可较好预测患者的治疗反应及结局。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhang XS, Qin YZ, Lai YY, et al. [Combination of socio-demographic and clinical co-variates for predicting treatment responses and outcomes in patients with chronic myeloid leukemia in the chronic phase]. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 35231994. doi:10.3760/cma.j.issn.0253-2727.2022.01.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。